Kronisk subdural hæmatom embolisering med afkoblingsspiraler (SEED)
Sikkerhed og effektivitet af kronisk subdural hæmatom embolisering med udskillelige spiraler
This is a prospective, multi-center, post market registry study designed to evaluate the safety and efficacy of treatment with Balt coils in patients with chronic subdural hematoma (cSDH).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The primary objective of this observational registry study is to assess the safety and efficacy of Balt Coils as an adjunct to middle meningeal artery (MMA) embolization in a real-world setting among patients undergoing treatment for chronic subdural hematoma (cSDH), and explore correlations between patient characteristics, clinical characteristics, and outcomes. By collecting comprehensive, real-world data, the registry will characterize procedural inputs, document clinical and radiographic outcomes, and explore variation in technique and practice setting. The overarching goal is to generate a more complete understanding of Middle Meningeal Artery Embolization (MMAE) in diverse clinical environments, inform future prospective studies, and guide evidence-based adoption of this evolving therapy. Patients may be treated with Balt coils regardless of enrollment in the study as the decision to place the coils should be made independently as per standard of care and prior to enrollment in the study.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Sukaina Davdani
- Telefonnummer: (212) 241-2524
- E-mail: Sukaina.Davdani@mountsinai.org
Undersøgelse Kontakt Backup
- Navn: Sydney Edwards
- Telefonnummer: (212) 241-2524
- E-mail: Sydney.Edwards@mountsinai.org
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forenede Stater, 85711
- Ikke rekrutterer endnu
- Carondelet Neurological Institute
-
Ledende efterforsker:
- Alexander Coon, MD
-
Kontakt:
- Matthew Pohlmeyer
- E-mail: Matthew.Pohlmeyer@tenethealth.org
-
-
California
-
San Deigo, California, Forenede Stater, 92093
- Ikke rekrutterer endnu
- University of California - San Deigo
-
Kontakt:
- Pete Chase
- E-mail: PChase@Health.UCSD.edu
-
Ledende efterforsker:
- David Santiago-Dieppa, MD
-
Walnut Creek, California, Forenede Stater, 94598
- Rekruttering
- John Muir Health
-
Ledende efterforsker:
- Benjamin Yim, MD
-
Kontakt:
- Melenie Aaron
- E-mail: Melenie.Aaron@JohnMuirHealth.com
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40292
- Ikke rekrutterer endnu
- University of Louisville
-
Kontakt:
- Mechelle Kaufman
- E-mail: Mechelle.Kaufman@louisville.edu
-
Ledende efterforsker:
- Isaac Josh Abecassis, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- Ikke rekrutterer endnu
- Oklahoma University Medical Center
-
Ledende efterforsker:
- Hakeem Shakir, MD
-
Kontakt:
- Michael Omimi
- E-mail: Michael-Omini@OU.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients with symptomatic chronic subdural hematoma (cSDH), with or without previous surgical evacuation that need additional treatment
Beskrivelse
Inclusion criteria:
- Age ≥ 18
- Patients experiencing unilateral or bilateral non-acute subdural hematoma confirmed by CT imaging. Acute on Chronic or mixed density hematoma allowed.
- A clinical decision has been made to use coiling and/or embolics as treatment, with or without surgical debridement, independently as per standard of care and prior to enrollment in the study.
- Signed informed consent obtained by patient or Legal Authorized Representative (LAR)
Exclusion criteria:
- Primary acute SDH
- Prior MMAE in target territory
- Premorbid mRS > 3
- Common carotid stenosis >70% or prior carotid stent placement
- Significant medical contraindication to angiography (kidney failure/disease)
- Anatomical variations that would make MMA embolization difficult or unsafe
- Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints
- Pregnancy
- Life expectancy ≤ 1 year
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: CASE_ONLY
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Participants with cSDH
All participants enrolled will be treated with the Balt coils.
|
MMA embolization utilizing Balt Coils
Andre navne:
surgical or bedside evacuation pre or post-surgical debridement |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in hematoma volume
Tidsramme: 180 days
|
Change in hematoma volume based on CT imaging |
180 days
|
|
Change in maximal thickness
Tidsramme: 180 days
|
Change in maximal thickness based on CT imaging |
180 days
|
|
Change in midline shift
Tidsramme: 180 days
|
Change in midline shift (mm) based on CT imaging |
180 days
|
|
Number of periprocedural major disabling stroke or any death
Tidsramme: 30 days
|
Number of periprocedural major disabling stroke or any death |
30 days
|
|
Number of participants with symptomatic recurrence progression requiring retreatment
Tidsramme: 180 days
|
Number of participants with symptomatic recurrence progression of the SDH requiring retreatment |
180 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Device-related adverse events (AE), serious adverse events (SAE), and procedural-related SAE
Tidsramme: 180 days
|
Number of Adverse events and serious adverse events related to the device as assessed by an independent medical monitor |
180 days
|
|
Number of Acute successful embolization of the target vessel
Tidsramme: Immediately post-procedure
|
Determination of successful embolization based on angiographic imaging |
Immediately post-procedure
|
|
Change in EuroQoL 5 dimensions 5 levels (EQ-5D-5L)
Tidsramme: 180 days
|
The EQ-5D is a generic instrument for describing and valuing health. The new version includes the 5 levels of severity in each of the existing five EQ-5D dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and now called the EQ-5D-5L, each assessed on a 5-point scale (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems). Participants score each dimension based on their health that day and their responses are used to generate a health index score. Index scores could range from <0 (a health state equivalent to dead with negative values representing a state worse than dead) to 1 (full health). Lower scores indicate a higher QoL. |
180 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Christopher Kellner, Icahn School of Medicine at Mount Sinai
- Ledende efterforsker: Benjamin Yim, John Muir Health
- Ledende efterforsker: Alexander Coon, Carondelet Neurological Institute
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Karsygdomme
- Hjerte-kar-sygdomme
- Sår og skader
- Patologiske processer
- Kronisk sygdom
- Sygdomsegenskaber
- Blødning
- Kraniocerebralt traume
- Traumer, nervesystemet
- Intrakranielle blødninger
- Intrakraniel blødning, traumatisk
- Patologiske tilstande, tegn og symptomer
- Hæmatom
- Hæmatom, subdural
- Hæmatom, subdural, kronisk
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- STUDY-25-01365
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Upon the completion of the study, Mount Sinai's data management team will clean and analyze all data in preparation of manuscript writing and publication. Data that will be shared and published will be that of all participants combined to protect individual patient privacy and confidentiality.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .